Literature DB >> 16475897

Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis.

Rudolf Mierau1, Ekkehard Genth.   

Abstract

Diagnosis of rheumatoid arthritis (RA) is mainly based on clinical criteria of symmetric polyarthritis of the hands and feet, with morning stiffness lasting usually more than 1 h. Autoantibodies typical for RA, i.e., rheumatoid factors and anti-cyclic citrullinated peptide, and measurements of inflammation add more specific information, especially for early diagnosis, where clinical presentation may be oligosymptomatic involving only a few joints. These laboratory parameters are also relevant for prognosis of disease persistence, functional impairment and radiological progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16475897     DOI: 10.1515/CCLM.2006.026

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative.

Authors:  Brian Walitt; Rachel Mackey; Lewis Kuller; Kevin D Deane; William Robinson; V Michael Holers; Yue-Fang Chang; Larry Moreland
Journal:  Am J Epidemiol       Date:  2013-03-13       Impact factor: 4.897

2.  Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis.

Authors:  Jing Cui; Kimberly E Taylor; Anita L Destefano; Lindsey A Criswell; Elena S Izmailova; Alex Parker; Ronenn Roubenoff; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; Elizabeth W Karlson
Journal:  Mol Med       Date:  2009-03-06       Impact factor: 6.354

3.  A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.

Authors:  Peter Taylor; Juliane Gartemann; Jeanie Hsieh; James Creeden
Journal:  Autoimmune Dis       Date:  2011-09-11

Review 4.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis.

Authors:  Denisa Predeteanu; Luminita Varzaru; Andra Balanescu; Violeta Bojinca; Daniela Opris; Violeta Vlad; Florian Berghea; Mihai Abobului; Cosmin Constantinescu; Ruxandra Ionescu
Journal:  J Med Life       Date:  2009 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.